menu

Keyword: brand-name drugs

From Brands to Generics - No Monopoly, No Competition (7/31/2002)

By providing incentives for brand-name drug companies to fund expensive R&D, temporary patents for expensive blockbuster drugs inadvertently lead to cheaper generic rivals when the patents expire.

Keywords: bioequivalent, brand-name drugs, competition, Generic drugs, Hatch-Waxman Act, monopoly, patent, prescription drugs

Power Play (7/31/2002)

Market competition requires a balance of power between buyers and sellers.

Keywords: balance of power, brand-name drugs, Generic drugs, Hatch-Waxman Act, HMO, managed care, patent, prescription drugs, Prozac